Microbiome therapeutics and patent protection

Obtaining patent protection for microbiome therapeutics has been affected profoundly by the US Supreme Court decisions in Myriad and Mayo , which redefined the scope of which natural phenomena, including microbiome therapeutics, are patent eligible.

Saved in:
Bibliographic Details
Published inNature biotechnology Vol. 38; no. 7; pp. 806 - 810
Main Authors FitzGerald, Mark J., Spek, Erik J.
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.07.2020
Nature Publishing Group
Subjects
631/326
631/61
706/703
Agriculture
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Biotechnology industry
Drug Industry - trends
Health aspects
Homeopathy
Humans
Intellectual property
Life Sciences
Materia medica and therapeutics
Microbiomes
Microbiota (Symbiotic organisms)
Microbiota - drug effects
Microbiota - genetics
Patents as Topic
State court decisions
Therapeutics
United States
Online AccessGet full text

Cover

More Information
Summary:Obtaining patent protection for microbiome therapeutics has been affected profoundly by the US Supreme Court decisions in Myriad and Mayo , which redefined the scope of which natural phenomena, including microbiome therapeutics, are patent eligible.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1087-0156
1546-1696
DOI:10.1038/s41587-020-0579-z